WA
CYTO

Wasatch Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History

Wasatch Advisors’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1
Closed -$90K – 335
2017
Q3 		$90K Hold
1
– – ﹤0.01% 325
2017
Q2 		$83K Hold
1
– – ﹤0.01% 340
2017
Q1 		$107K Hold
1
– – ﹤0.01% 343
2016
Q4 		$124K Sell
1
-16
-94% -$1.59M ﹤0.01% 360
2016
Q3 		$2.38M Sell
17
-18
-51% -$4.29M 0.04% 244
2016
Q2 		$11.6M Hold
35
– – 0.18% 123
2016
Q1 		$9.68M Hold
35
– – 0.15% 140
2015
Q4 		$13.6M Buy
35
+2
+6% +$576K 0.19% 128
2015
Q3 		$9.41M Sell
33
-1
-3% -$383K 0.13% 168
2015
Q2 		$13.4M Buy
+34
New +$14.1M 0.15% 162
2015
Q1 		– Hold
0
– – – 372

Other funds holding CYTO

SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wasatch Advisors's CYTO Position: Q4 2017 in Review

Wasatch Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2017, closing a stake of 1 share — an estimated $90K sold.

Wasatch Advisors first reported a position in CYTO in Q2 2015 and held it in 10 quarters. The position peaked at $13.6M in Q4 2015. 8 funds tracked by Wall St. Rank hold CYTO as of Q4 2017.

  • Wasatch Advisors reported no remaining Altamira Therapeutics Ltd position as of Q4 2017 after selling out during the quarter.
  • Wasatch Advisors sold 1 Altamira Therapeutics Ltd share in Q4 2017, an estimated $90K.
  • Wasatch Advisors first reported a position in Altamira Therapeutics Ltd in Q2 2015 and held it in 10 quarters.
  • Wasatch Advisors's Altamira Therapeutics Ltd position peaked at $13.6M in Q4 2015.
  • 8 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2017.

Based on Wasatch Advisors's 13F filing for Q4 2017, filed 16 Jan 2018.